Israeli Biotech Company Uses Cannabis & Mushrooms To Eliminate 90% Of Colon Cancer Cells

With a regulated cannabis space comes ample research and helpful findings regarding how the plant can aid various conditions and illnesses. The latest news comes from a biotech company in Israel, Cannabotech, which creates scientifically-formulated medical products using cannabis and fungi. 

Cannabotech noted in a press release on Tuesday that its “Integrative-Colon” products have been shown to eliminate over 90% of cancer cells in the colon. It’s said that this particular formulation was created by combining various cannabinoids derived from the cannabis plant and other mushroom extracts. 

The Cannabotech team tested its Integrative-Colon products on individuals with different colon cancer subtypes to make this conclusion. What’s rather interesting is how Cannabotech notes how the Integrative-Colon formulation worked significantly better than administering each cannabinoid individually, meaning a synergistic relationship caused the decrease in cancer cells. 

The team made it clear that it’s not likely a specific individual strain would offer the benefits like their Integrative-Colon formulation, meaning science-backed research and examinations are needed when conducting such experiments. 

While the cannabinoids were individually extracted from the cannabis plant, the mushroom extracts were enriched with PSK, a substance that’s extracted from the Trametes mushroom that’s often used in oncology treatment in Asia. 

Physicians will begin administering the formulation in Israel next month alongside chemotherapy sessions to examine how well it’s working. In the press release, the CEO of Cannabotech, Elhanan Shaked, mentioned that his company had just reached a “significant milestone” to position itself as a “leader in integrative oncology medicine.” 

Furthermore, Shaked notes that his company’s solutions will first launch in Israel, then over to the U.S. during the second half of 2022, all while the company keeps its goal to “define a new standard for the medical cannabis industry.”

The press release also notes Cannabotech’s pharmacological consultant, Isaac Angel explaining, “The significant synergistic effect demonstrated by the combination of active ingredients eliminated over 90% of all types of cancer cells used in the study.”

Angel added that it was helpful to achieve these findings without the presence of psychoactive THC, “whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types.”